Copeptin independently predicts poor outcome within 3 months, mortality within 3 months and complications (symptomatic intracerebral hemorrhage, space-occupying cerebral edema, pneumonia, seizures or mortality within 10 days from stroke onset). This evidence concerns the gene AVP and susceptibility to pneumonia measurement.